Figure 6. TA99 anti-tumor antibodies improved the outcome of treatment with combined targeted therapy and ICB in BRAFV600E-mutant subcutaneous YUMM melanoma.
C57BL/6 mice bearing YUMM1.7 subcutaneous melanoma were treated with MEKi, anti-immune checkpoint antibodies, or TA99 as single-agent therapies or in different simultaneous combinations (A) and differences in tumor growth were determined. The triple combination showed a significantly increased latency and reduced tumor size (B). Differences in tumor growth were determined by two-way ANOVA with Bonferroni correction (n = 4 mice per group). *** p < 0.0001. Both triple combinations show a significant increased control of tumor growth when compared with untreated control and with single and double agent treatment.